
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London; 2 Hedley Atkins/Cancer Research UK Breast Pathology Laboratory, Guys Hospital, London; 3 Ludwig Institute for Cancer Research, University College London; 4 Department of Histopathology, St. James Hospital, Leeds; and 5 Department of Histopathology, Royal Marsden Hospital, London, United Kingdom
ABSTRACT
Tumor grade is an established indicator of breast cancer outcome, although considerable heterogeneity exists even within-grade. Around 25% of grade III invasive ductal breast carcinomas are associated with a "basal" phenotype, and these tumors are reported to be a distinct subgroup. We have investigated whether this group of breast cancers has a distinguishing pattern of genetic alterations and which of these may relate to the different clinical outcome of these patients. We performed comparative genomic hybridization (CGH) analysis on 43 grade III invasive ductal breast carcinomas positive for basal cytokeratin 14, as well as 43 grade- and age-matched CK14-negative controls, all with up to 25 years (median, 7 years) of clinical follow-up. Significant differences in CGH alterations were seen between the two groups in terms of mean number of changes (CK14+ve 6.5, CK14ve 10.3; P = 0.0012) and types of alterations at chromosomes 4q, 7q, 8q, 9p, 13q, 16p, 17p, 17q, 19p, 19q, 20p, 20q and Xp. Supervised and unsupervised algorithms separated the two groups on CGH data alone with 76% and 74% accuracy, respectively. Hierarchical clustering revealed distinct subgroups, one of which contained 18 (42%) of the CK14+ve tumors. This subgroup had significantly shorter overall survival (P = 0.0414) than other grade III tumors, regardless of CK14 status, and was an independent prognostic marker (P = 0.031). These data provide evidence that the "basal" phenotype on its own does not convey a poor prognosis. Basal tumors are also heterogeneous with only a subset, identifiable by pattern of genetic alterations, exhibiting a shorter overall survival. Robust characterization of this basal group is necessary if it is to have a major impact on management of patients with breast cancer.
This article has been cited by other articles:
![]() |
A. A. Luck, A. J. Evans, J. J. James, E. A. Rakha, E. C. Paish, A. R. Green, and I. O. Ellis Breast Carcinoma with Basal Phenotype: Mammographic Findings Am. J. Roentgenol., August 1, 2008; 191(2): 346 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rapaport, E. Barillot, and J.-P. Vert Classification of arrayCGH data using fused SVM Bioinformatics, July 1, 2008; 24(13): i375 - i382. [Abstract] [PDF] |
||||
![]() |
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis Basal-Like Breast Cancer: A Critical Review J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Korsching, S S Jeffrey, W Meinerz, T Decker, W Boecker, and H Buerger Basal carcinoma of the breast revisited: an old entity with new interpretations J. Clin. Pathol., May 1, 2008; 61(5): 553 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oda, H. Satake, A. Nishio, S. Ichihara, Y. Shimoyama, T. Imai, and M. Nagino Radiologic-Pathologic Conferences of the Nagoya University Hospital: Centrally Necrotizing Carcinoma of the Breast Am. J. Roentgenol., April 1, 2008; 190(4): W237 - W239. [Full Text] [PDF] |
||||
![]() |
S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benitez, and J. Palacios Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J. Clin. Pathol., September 1, 2007; 60(9): 1006 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, and S. A. Narod Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence Clin. Cancer Res., August 1, 2007; 13(15): 4429 - 4434. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Savage, M. B.K. Lambros, D. Robertson, R. L. Jones, C. Jones, A. Mackay, M. James, J. L. Hornick, E. M. Pereira, F. Milanezi, et al. Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis Clin. Cancer Res., January 1, 2007; 13(1): 90 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Cheng, C.-F. Horng, M. West, E. Huang, J. Pittman, M.-H. Tsou, H. Dressman, C.-M. Chen, S. Y. Tsai, J. J. Jian, et al. Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer J. Clin. Oncol., October 1, 2006; 24(28): 4594 - 4602. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Laakso, M. Tanner, J. Nilsson, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Bergh, and J. Isola Basoluminal carcinoma: a new biologically and prognostically distinct entity between Basal and luminal breast cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4185 - 4191. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Banerjee, J S Reis-Filho, S Ashley, D Steele, A Ashworth, S R Lakhani, and I E Smith Basal-like breast carcinomas: clinical outcome and response to chemotherapy J. Clin. Pathol., July 1, 2006; 59(7): 729 - 735. [Abstract] [Full Text] [PDF] |
||||
![]() |
A E Pinto, L Roque, R Rodrigues, S Andre, and J Soares Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation J. Clin. Pathol., April 1, 2006; 59(4): 367 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
J S Reis-Filho, C Westbury, and J-Y Pierga The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, D. Hardisson, F. Calero, J. Benitez, and J. Palacios Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas Clin. Cancer Res., March 1, 2006; 12(5): 1533 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Stange, B. Radlwimmer, F. Schubert, F. Traub, A. Pich, G. Toedt, F. Mendrzyk, U. Lehmann, R. Eils, H. Kreipe, et al. High-Resolution Genomic Profiling Reveals Association of Chromosomal Aberrations on 1q and 16p with Histologic and Genetic Subgroups of Invasive Breast Cancer Clin. Cancer Res., January 15, 2006; 12(2): 345 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Lakhani, J. S. Reis-Filho, L. Fulford, F. Penault-Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benitez, C. Rivas, Y.-J. Bignon, et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype Clin. Cancer Res., July 15, 2005; 11(14): 5175 - 5180. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |